Overactive bladders could become the next big frontier for Botox, the anti-wrinkle drug, later this year. It would significantly boost sales of the $1.5 billion-a-year product, according to Allergan Inc.’s chief executive, David Pyott.
Allergan earlier on Wednesday reported earnings growth for the second-quarter, fueled largely by sales of Botox for smoothing wrinkles and for a growing range of medical uses.
Overactive bladder, caused by uncontrollable contractions of the organ, causes frequent urination, urgent need to urinate and inability to control urination.
“Current drugs for overactive bladder just don’t work that well,” Pyott said in an interview, “and studies show that after a year, 70 percent of patients don’t respond to treatment.”
Standard treatments, pills called anticholinergics, including oxybutynin and GlaxoSmithKline PLC’s Vesicare, are associated with dry mouth and can cause constipation and other side effects.
A single injection of Botox into the bladder can provide significant relief for up to nine months and significantly improve quality of life, Pyott said, particularly for adults who now need to wear diapers.